The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. The product is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. The product is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with The product alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. The product is also indicated to accelerate the engraftment of these cells after their reinfusion. The product is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmanns syndrome).
* VAT and and shipping costs not included. Errors and price changes excepted
